Brief: Xvivo Perfusion: Perfadex Plus Approved By The FDA
June 25 (Reuters) - XVIVO PERFUSION AB XVIVO.ST :
* PERFADEX PLUS APPROVED BY THE FDA
Source text for Eikon: ID:nWkr4KpjdL
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength